Journal of Pain & Palliative Care Pharmacotherapy最新文献_第10页

A Multicenter Retrospective Observational Study Analyzing the Effect of Polypharmacy on Oxycodone Tolerability. 一项多中心回顾性观察研究，分析多重用药对羟考酮耐受性的影响。

IF 1.1

Journal of Pain & Palliative Care Pharmacotherapy Pub Date : 2024-03-01 Epub Date: 2024-01-16 DOI: 10.1080/15360288.2023.2301341

Katsuya Makihara, Yoshihiro Yamamoto, Masayuki Miyazaki, Maho Taguchi, Junya Sato, Hisamitsu Takase, Yasuhito Uezono

{"title":"A Multicenter Retrospective Observational Study Analyzing the Effect of Polypharmacy on Oxycodone Tolerability.","authors":"Katsuya Makihara, Yoshihiro Yamamoto, Masayuki Miyazaki, Maho Taguchi, Junya Sato, Hisamitsu Takase, Yasuhito Uezono","doi":"10.1080/15360288.2023.2301341","DOIUrl":"10.1080/15360288.2023.2301341","url":null,"abstract":"Polypharmacy is becoming increasingly troublesome in the treatment of cancer. The aim of this study was to explore the effects of concomitant polypharmacy comprising drugs that inhibit CYP3A4 and/or CYP2D6 on the oxycodone tolerability in patients with cancer. We conducted a multicenter retrospective study encompassing 20 hospitals. The data used for the study were obtained during the first 2 wk of oxycodone administration. The incidence of oxycodone discontinuation or dose reductions due to side effects and oxycodone-induced nausea and vomiting (OINV) were compared between patients not treated with either inhibitor and those treated with concomitant CYP3A4 or CYP2D6 inhibitors. The incidence of oxycodone discontinuation or dose reductions in patients treated with ≥3 concomitant CYP2D6 inhibitors (18.2%) tended to be higher than that in patients without this treatment (8.2%; p = 0.09). Moreover, the incidence of OINV in patients treated with 2 concomitant CYP3A4 inhibitors (29.8%) was significantly higher than that in patients without this treatment (15.5%; p = 0.049). Multivariate analysis showed that more than two concomitant CYP3A4 inhibitors and no concomitant use of naldemedine were independent risk factors for OINV. Concomitant polypharmacy involving CYP3A4 inhibitors increases the risk of OINV. Therefore, medications concomitantly used with oxycodone should be optimized.","PeriodicalId":16645,"journal":{"name":"Journal of Pain & Palliative Care Pharmacotherapy","volume":" ","pages":"3-12"},"PeriodicalIF":1.1,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139478515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Polypharmacy and Reversible Drug Induced QT Prolongation in a Patient with Advanced Cancer: Case Report. 一名晚期癌症患者的多重用药和可逆药物诱发的 QT 间期延长：病例报告。

IF 1.1

Journal of Pain & Palliative Care Pharmacotherapy Pub Date : 2024-03-01 Epub Date: 2024-01-05 DOI: 10.1080/15360288.2023.2297218

Gabriela Cerdà, Joaquim Julià-Torras, Jesús González-Barboteo, Margarita Romeo, Agnès Calsina-Berna

引用次数: 0

"I Just Don't Feel Heard": A Case Study on Opioid Use Disorder and Pain Management. “我只是不觉得被听到”:阿片类药物使用障碍和疼痛管理的案例研究。

IF 1.1

Journal of Pain & Palliative Care Pharmacotherapy Pub Date : 2023-12-01 Epub Date: 2023-08-28 DOI: 10.1080/15360288.2023.2250340

Aila Malik, Peter D Vu, A Sarah Cohen, Vishal Bansal, Morgan R Cowan, Gregory M Blazek, Tiffany Champagne-Langabeer

引用次数: 0

Using Interdisciplinary Teams to Mitigate the Effects of Drug Shortages in Palliative Care: The Case of Lorazepam Injection. 使用跨学科团队减轻姑息治疗中药物短缺的影响：以洛拉西泮注射液为例。

IF 1.1

Journal of Pain & Palliative Care Pharmacotherapy Pub Date : 2023-12-01 Epub Date: 2023-11-28 DOI: 10.1080/15360288.2023.2269899

Natalie Hartung, Zainab Fatima, Danielle M Noreika, J Brian Cassel, Katie S Adams

{"title":"Using Interdisciplinary Teams to Mitigate the Effects of Drug Shortages in Palliative Care: The Case of Lorazepam Injection.","authors":"Natalie Hartung, Zainab Fatima, Danielle M Noreika, J Brian Cassel, Katie S Adams","doi":"10.1080/15360288.2023.2269899","DOIUrl":"10.1080/15360288.2023.2269899","url":null,"abstract":"Given the rising frequency of drug shortages in hospitals, interdisciplinary collaboration is necessary to manage medications, modify electronic medical records, and evaluate safety outcomes. One such shortage impacted lorazepam injection, a medication commonly used in palliative care to treat anxiety, agitation, and seizures. In anticipation of the lorazepam shortage in the summer of 2022, pharmacy staff collaborated with palliative care physicians to identify alternative treatment recommendations when providers were prohibited from ordering lorazepam injection. Before the shortage, lorazepam was used an average of 95 times per month on the palliative care unit. The overall use of benzodiazepines decreased substantially following the recommendation for the therapeutic alternative, midazolam, during the shortage. Once the shortage ended, use roughly returned to pre-shortage baselines. During this time, there were no patient safety events documented on the palliative care unit. Moreover, no changes to the care experience were reported by patients, family/caregivers, providers, or staff. The collaborative effort between pharmacy and palliative care specialists resulted in alternative treatments for palliative care patients during the drug shortage. This preserved the hospital's supply of lorazepam injection for a patient population with no suitable alternatives while still allowing for management of palliative patients.","PeriodicalId":16645,"journal":{"name":"Journal of Pain & Palliative Care Pharmacotherapy","volume":" ","pages":"336-341"},"PeriodicalIF":1.1,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49691008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Oxygen Therapy in the Last Days and Hours of Life: From Evidence to Practice. 氧气疗法在生命的最后几天和几个小时:从证据到实践。

IF 0.9

Journal of Pain & Palliative Care Pharmacotherapy Pub Date : 2023-12-01 Epub Date: 2023-09-07 DOI: 10.1080/15360288.2023.2250332

Mónica Carqueijó

引用次数: 0

Mpox Pain Management with Topical Agents: A Case Series. m痘疼痛管理与局部药物:一个案例系列。

IF 0.9

Journal of Pain & Palliative Care Pharmacotherapy Pub Date : 2023-12-01 Epub Date: 2023-08-31 DOI: 10.1080/15360288.2023.2250762

Mariam Shabbir, Maria Lorraine Bugayong, Michael Anthony DeVita

引用次数: 0

Effects of Opioids, Steroids, Benzodiazepines, Anticholinergics, and Antihistamines on the Efficacy of Antipsychotics for Treating Delirium in End-of-Life Adult Patients Undergoing Palliative Care. 阿片类药物、类固醇、苯二氮卓类药物、抗胆碱能药物和抗组胺药物对接受姑息治疗的临终成人患者谵妄的抗精神病药物疗效的影响

IF 1.1

Journal of Pain & Palliative Care Pharmacotherapy Pub Date : 2023-12-01 Epub Date: 2023-09-13 DOI: 10.1080/15360288.2023.2253241

Junya Sato, Rei Tanaka

{"title":"Effects of Opioids, Steroids, Benzodiazepines, Anticholinergics, and Antihistamines on the Efficacy of Antipsychotics for Treating Delirium in End-of-Life Adult Patients Undergoing Palliative Care.","authors":"Junya Sato, Rei Tanaka","doi":"10.1080/15360288.2023.2253241","DOIUrl":"10.1080/15360288.2023.2253241","url":null,"abstract":"The purpose of the study was to determine the effect of combination therapy involving opioids, steroids, benzodiazepines, anticholinergics, and antihistamines on antipsychotics efficacy for delirium. The study included adult inpatients receiving end-of-life palliative care and diagnosed with hyperactive delirium. Changes in delirium symptoms were assessed using the Intensive Care Delirium Screening Checklist (ICDSC). A retrospective analysis was conducted on 97 patients with ICDSC scores of ≥4, comparing the scores before and after antipsychotic administration. A mean score <4 sustained for 3 days after antipsychotics administration was considered effective. The mean days with ICDSC <4 within a 3-day period were evaluated as well. The efficacy of antipsychotics was compared between cases with and without the use of opioids, steroids, benzodiazepines, anticholinergics, and antihistamines. The results revealed no significant differences in the efficacy of antipsychotics for delirium when used in conjunction with opioids (odds ratio 0.614, 95% CI [0.179-2.105]), benzodiazepines (0.387, [0.108-1.390]), steroids (1.258, [0.276-5.746]), or anticholinergics (2.085, [0. 148-29.458]). Additionally, no significant differences were observed in the mean days with ICDSC <4 within 3-day period. Although opioids, benzodiazepines, steroids, anticholinergics, and antihistamines are recognized as delirium risk factors, their use for symptom relief in patients with delirium may not affect antipsychotic efficacy.","PeriodicalId":16645,"journal":{"name":"Journal of Pain & Palliative Care Pharmacotherapy","volume":" ","pages":"298-307"},"PeriodicalIF":1.1,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10225778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Suspected Buprenorphine-Precipitated Opioid Withdrawal following Intercourse: A Case Report. 性交后疑似丁丙诺啡沉淀阿片类药物戒断一例报告。

IF 1.1

Journal of Pain & Palliative Care Pharmacotherapy Pub Date : 2023-12-01 Epub Date: 2023-08-28 DOI: 10.1080/15360288.2023.2250344

Davene Lynch, Lyndsey Chitty, Brittany Johnson, Amie L Hoefnagel

引用次数: 1

Oxycodone Extended-Release Capsule Utilization for Pain Management in a Cancer Palliative Care Clinic: A Retrospective Review. 羟考酮缓释胶囊用于癌症姑息治疗临床疼痛管理:回顾性回顾。

IF 1.1

Journal of Pain & Palliative Care Pharmacotherapy Pub Date : 2023-12-01 Epub Date: 2023-09-13 DOI: 10.1080/15360288.2023.2253248

Jordan Fortunato, Justin Kullgren, Gary Houchard, Jessica Hirsch, Nicole Shirilla, Meridith Bumb, Junan Li

{"title":"Oxycodone Extended-Release Capsule Utilization for Pain Management in a Cancer Palliative Care Clinic: A Retrospective Review.","authors":"Jordan Fortunato, Justin Kullgren, Gary Houchard, Jessica Hirsch, Nicole Shirilla, Meridith Bumb, Junan Li","doi":"10.1080/15360288.2023.2253248","DOIUrl":"10.1080/15360288.2023.2253248","url":null,"abstract":"Xtampza ER™, an oxycodone extended-release capsule (OERC), was the first long-acting opioid to feature abuse-deterrent properties and various routes of administration without pharmacokinetic alterations. The primary objective of this study was to evaluate changes in reported pain scores after initiation of or rotation to OERC from a previous opioid.  Baseline scores were from patients' outpatient visits immediately before starting OERC and were compared to those at the next two follow-up visits. Secondary objectives identified variables that influenced pain scores. Methods included screening for cancer patients with outpatient OERC prescriptions seen in the palliative care clinic. Eighty-two charts were reviewed with 66 included. Overall mean pain scores at both follow-ups were lower than those at baseline (-0.7 ± 2.1; -1.1 ± 2.4). Results were statistically significant between first and second-reported pain scores versus baseline (p = 0.009; 0.012) but clinically insignificant, defined as a ≥ 2-point change in numeric pain scores. Most patients discontinued OERC at the first or second follow-up (35; 53%), and 12.1% of patients who started OERC were prescribed OERC at the end of the study. There were no significant variables identified to influence pain scores either statistically or clinically. Further studies are needed to determine the long-term efficacy and safety in cancer palliative-care patients.","PeriodicalId":16645,"journal":{"name":"Journal of Pain & Palliative Care Pharmacotherapy","volume":" ","pages":"286-297"},"PeriodicalIF":1.1,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10279171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Peer Review Questions & Answers: How? Part III: Writing the Reviewer Report. 同行评议问答:怎么做?第三部分:撰写审稿人报告。

IF 0.9

Journal of Pain & Palliative Care Pharmacotherapy Pub Date : 2023-12-01 Epub Date: 2023-11-28 DOI: 10.1080/15360288.2023.2271817

Laura Meyer-Junco

引用次数: 0